Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2024 Sep-Oct;52(7):732-739.
doi: 10.1111/ceo.14407. Epub 2024 Jun 6.

Matched case-control comparison of surgical success after XEN45 Gel Stent and PRESERFLO MicroShunt implantation in a Caucasian population

Jan Niklas Lüke  1 , Thomas S Dietlein  1 , Randolf A Widder  2 , Gernot F Roessler  2   3 , Vincent Lüke  1 , Philip Enders  1 , Alexandra Lappa  1 , David Kiessling  2
Affiliations
Comparative Study

Matched case-control comparison of surgical success after XEN45 Gel Stent and PRESERFLO MicroShunt implantation in a Caucasian population

Jan Niklas Lüke et al. Clin Exp Ophthalmol. 2024 Sep-Oct.

Abstract

Background: The aim of this study was to compare the outcome of implantation of a XEN45 Gel Stent with the outcome of implantation of a Preserflo MicroShunt in a matched-pair analysis in eyes being naïve to filtering surgery.

Methods: In this comparative, retrospective study, 50 eyes that had undergone XEN45 Gel Stent implantation were compared with 50 eyes after Preserflo implantation. Follow-up was at least 6 months, and surgical success was measured by criteria A (IOP < 21 mmHg, IOP reduction >20%, no repeat surgery); criteria B (IOP < 18 mmHg, IOP reduction >20%, no repeat surgery); and criteria C (IOP ≤15 mmHg, IOP reduction ≥40%, no repeat surgery).

Results: After a follow-up period of 12 months, mean IOP had decreased from preoperative 25.2 ± 4.8 mmHg in the XEN group to 14.5 ± 4.0 (n = 35) and from 25.3 ± 6.8 mmHg to 11.9 ± 2.9 (n = 41) in the Preserflo group, respectively. The IOP at the last follow-up of the two groups differed significantly (p < 0.01). The probability of surgical success did not differ concerning Criteria A and B, but surgical success was significantly higher in the Preserflo group for Criteria C (60%, p < 0.01).

Conclusion: Both the Preserflo and XEN45 Gel Stent provide an effective and safe treatment option for advanced glaucoma and have a high potential to reduce intraocular pressure. Absolute IOP levels of <16 mmHg after 12 months were significantly more frequent in the Preserflo group.

Keywords: MIGS; glaucoma; intraocular pressure; rebound tonometry; trabeculectomy.

PubMed Disclaimer

References

REFERENCES

    1. Kirwan JF, Lockwood AJ, Shah P, et al. Trabeculectomy in the 21st century. Ophthalmology. 2013;120(12):2532‐2539.
    1. Widder RA, Lappas A, Rennings C, Hild M, Dietlein TS, Roessler GF. Primary versus posttrabeculectomy XEN45 gel stent implantation: comparison of success rates and intraocular pressure‐lowering potential in pseudophakic eyes. J Glaucoma. 2020;29(12):1115‐1119.
    1. Pinchuk L. The use of polyisobutylene‐based polymers in ophthalmology. Bioact Mater. 2022;10:185‐194.
    1. Arrieta EA, Aly M, Parrish R, et al. Clinicopathologic correlations of poly‐(styrene‐b‐isobutylene‐b‐styrene) glaucoma drainage devices of different internal diameters in rabbits. Ophthalmic Surg Lasers Imaging. 2011;42(4):338‐345.
    1. Lüke JN, Reinking N, Dietlein TS, Haendel A, Enders P, Lappas A. Intraoperative primary partial occlusion of the PreserFlo MicroShunt to prevent initial postoperative hypotony. Int Ophthalmol. 2023;43:2643‐2651. doi:10.1007/s10792‐023‐02664‐8

Publication types

LinkOut - more resources